Schizophrenia Clinical Trials in Bryant, Arkansas

4 studies are recruiting for schizophrenia in Bryant, Arkansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Neurocrine Clinical Site, Bryant, Arkansas
    Locations
    19 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07105111 on ClinicalTrials.gov

  2. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage
    Not phased
    Ages
    18 and older
    Site
    SanRo Clinical Research Group, Bryant, Arkansas
    Locations
    55 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Bryant, Arkansas
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  4. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Bryant, Arkansas
    Locations
    21 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT06963034 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.